WO2004059001A2 - Procede de determination de marqueurs de la peau du visage humain - Google Patents
Procede de determination de marqueurs de la peau du visage humain Download PDFInfo
- Publication number
- WO2004059001A2 WO2004059001A2 PCT/EP2003/014068 EP0314068W WO2004059001A2 WO 2004059001 A2 WO2004059001 A2 WO 2004059001A2 EP 0314068 W EP0314068 W EP 0314068W WO 2004059001 A2 WO2004059001 A2 WO 2004059001A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- skin
- proteins
- mrna molecules
- facial skin
- fragments
- Prior art date
Links
- 230000001815 facial effect Effects 0.000 title claims abstract description 291
- 238000000034 method Methods 0.000 title claims abstract description 108
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 245
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 181
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 176
- 239000012634 fragment Substances 0.000 claims abstract description 94
- 230000013632 homeostatic process Effects 0.000 claims abstract description 79
- 238000000018 DNA microarray Methods 0.000 claims abstract description 31
- 239000002537 cosmetic Substances 0.000 claims abstract description 22
- 238000000338 in vitro Methods 0.000 claims abstract description 18
- 238000010998 test method Methods 0.000 claims abstract description 7
- 238000012216 screening Methods 0.000 claims abstract description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 5
- 238000003149 assay kit Methods 0.000 claims abstract description 4
- 210000000481 breast Anatomy 0.000 claims description 104
- 230000014509 gene expression Effects 0.000 claims description 81
- 239000000203 mixture Substances 0.000 claims description 76
- 238000003196 serial analysis of gene expression Methods 0.000 claims description 43
- 239000000523 sample Substances 0.000 claims description 29
- 238000012360 testing method Methods 0.000 claims description 29
- 230000006735 deficit Effects 0.000 claims description 18
- 201000010099 disease Diseases 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 239000004480 active ingredient Substances 0.000 claims description 16
- 241000282412 Homo Species 0.000 claims description 11
- 150000007523 nucleic acids Chemical class 0.000 claims description 9
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 239000002299 complementary DNA Substances 0.000 claims description 7
- 238000009396 hybridization Methods 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 238000011002 quantification Methods 0.000 claims description 7
- 238000012163 sequencing technique Methods 0.000 claims description 7
- 238000000539 two dimensional gel electrophoresis Methods 0.000 claims description 6
- 239000003298 DNA probe Substances 0.000 claims description 4
- 238000000636 Northern blotting Methods 0.000 claims description 4
- 238000010240 RT-PCR analysis Methods 0.000 claims description 4
- 102000006382 Ribonucleases Human genes 0.000 claims description 4
- 108010083644 Ribonucleases Proteins 0.000 claims description 4
- 238000002474 experimental method Methods 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 3
- 108020004711 Nucleic Acid Probes Proteins 0.000 claims description 3
- 238000001042 affinity chromatography Methods 0.000 claims description 3
- 238000010668 complexation reaction Methods 0.000 claims description 3
- 238000001514 detection method Methods 0.000 claims description 3
- 238000010195 expression analysis Methods 0.000 claims description 3
- 238000004949 mass spectrometry Methods 0.000 claims description 3
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 claims description 3
- 239000002853 nucleic acid probe Substances 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 2
- 230000009870 specific binding Effects 0.000 claims description 2
- 230000008491 skin homeostasis Effects 0.000 claims 1
- 239000013543 active substance Substances 0.000 abstract description 9
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 210000003491 skin Anatomy 0.000 description 319
- 210000001519 tissue Anatomy 0.000 description 49
- 210000004027 cell Anatomy 0.000 description 20
- 238000004458 analytical method Methods 0.000 description 18
- 239000000047 product Substances 0.000 description 13
- 230000009274 differential gene expression Effects 0.000 description 7
- 238000001690 micro-dialysis Methods 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 239000011521 glass Substances 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 238000003491 array Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 239000012876 carrier material Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 210000003780 hair follicle Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- SJECZPVISLOESU-UHFFFAOYSA-N 3-trimethoxysilylpropan-1-amine Chemical compound CO[Si](OC)(OC)CCCN SJECZPVISLOESU-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000001723 extracellular space Anatomy 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- WIGIZIANZCJQQY-UHFFFAOYSA-N 4-ethyl-3-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]-oxomethyl]sulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(C)CC2)C=C1 WIGIZIANZCJQQY-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 101001007348 Arachis hypogaea Galactose-binding lectin Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 1
- 201000009053 Neurodermatitis Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 238000007622 bioinformatic analysis Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000000716 merkel cell Anatomy 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 201000004477 skin sarcoma Diseases 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- BPSIOYPQMFLKFR-UHFFFAOYSA-N trimethoxy-[3-(oxiran-2-ylmethoxy)propyl]silane Chemical compound CO[Si](OC)(OC)CCCOCC1CO1 BPSIOYPQMFLKFR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6881—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from skin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/148—Screening for cosmetic compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
La présente invention concerne un procédé de détermination in vitro de l'homéostasie de la peau du visage humain, des ensembles de test, des puces biologiques destinées à la détermination de marqueurs de la peau du visage humain, ainsi que l'utilisation de protéines, de molécules d'ARNm ou de fragments de protéines ou de molécules d'ARNm en tant que marqueurs de la peau du visage humain. L'invention concerne également un procédé de test destiné à la détection de l'efficacité d'agents cosmétiques ou pharmaceutiques destinés au traitement de la peau du visage humain, un procédé de criblage destiné à l'identification d'agents cosmétiques ou pharmaceutiques destinés au traitement de la peau du visage humain, ainsi qu'un procédé de fabrication d'une composition cosmétique ou pharmaceutique destinée au traitement de la peau du visage humain.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2003293839A AU2003293839A1 (en) | 2002-12-20 | 2003-12-11 | Method for determining markers of human facial skin |
| EP03789223A EP1573064A2 (fr) | 2002-12-20 | 2003-12-11 | Procede de determination de marqueurs de la peau du visage humain |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10260928.4 | 2002-12-20 | ||
| DE2002160928 DE10260928A1 (de) | 2002-12-20 | 2002-12-20 | Verfahren zur Bestimmung von Markern humaner Gesichtshaut |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2004059001A2 true WO2004059001A2 (fr) | 2004-07-15 |
| WO2004059001A3 WO2004059001A3 (fr) | 2005-03-03 |
Family
ID=32477976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2003/014068 WO2004059001A2 (fr) | 2002-12-20 | 2003-12-11 | Procede de determination de marqueurs de la peau du visage humain |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1573064A2 (fr) |
| AU (1) | AU2003293839A1 (fr) |
| DE (1) | DE10260928A1 (fr) |
| WO (1) | WO2004059001A2 (fr) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2866233A1 (fr) * | 2004-02-18 | 2005-08-19 | Vincience | Composition dermatologique et/ou cosmetique contenant des polypeptides |
| WO2015031708A1 (fr) * | 2013-08-30 | 2015-03-05 | The Procter & Gamble Company | Procédés d'identification d'agents cosmétiques pour le traitement d'une dyschromie périorbitaire et systèmes associés |
| US9168215B2 (en) | 2009-07-16 | 2015-10-27 | L'oreal | Cosmetic use of lacritin-type polypeptides |
| NO20170739A1 (en) * | 2017-05-04 | 2018-11-05 | Patogen As | Novel virus in Fish and Method for detection |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015105190A1 (fr) * | 2014-01-10 | 2015-07-16 | 学校法人順天堂 | Méthode d'évaluation du potentiel métastatique du cancer de l'endomètre en direction des ganglions lymphatiques |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001091700A2 (fr) * | 2000-05-30 | 2001-12-06 | Connective Tissue Imagineering Llc | Composition et procede destine a ameliorer l'elasticite des tissus |
| WO2002053773A2 (fr) * | 2001-01-03 | 2002-07-11 | Henkel Kommanditgesellschaft Auf Aktien | Procede pour la determination in vitro des agressions ou du vieillissement cutanes |
| WO2002053778A2 (fr) * | 2001-01-05 | 2002-07-11 | Genomicfx, Inc. | Methode de quantification relative d'acides nucleiques lies |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5866330A (en) * | 1995-09-12 | 1999-02-02 | The Johns Hopkins University School Of Medicine | Method for serial analysis of gene expression |
| DE19819889A1 (de) * | 1998-05-04 | 1999-11-11 | Fraunhofer Ges Forschung | Verfahren zur Isolierung von Nucleinsäuren |
| AU3931699A (en) * | 1998-05-04 | 1999-11-23 | Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. | Method and device for isolating nucleic acids |
-
2002
- 2002-12-20 DE DE2002160928 patent/DE10260928A1/de not_active Withdrawn
-
2003
- 2003-12-11 AU AU2003293839A patent/AU2003293839A1/en not_active Abandoned
- 2003-12-11 EP EP03789223A patent/EP1573064A2/fr not_active Withdrawn
- 2003-12-11 WO PCT/EP2003/014068 patent/WO2004059001A2/fr not_active Application Discontinuation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001091700A2 (fr) * | 2000-05-30 | 2001-12-06 | Connective Tissue Imagineering Llc | Composition et procede destine a ameliorer l'elasticite des tissus |
| WO2002053773A2 (fr) * | 2001-01-03 | 2002-07-11 | Henkel Kommanditgesellschaft Auf Aktien | Procede pour la determination in vitro des agressions ou du vieillissement cutanes |
| WO2002053778A2 (fr) * | 2001-01-05 | 2002-07-11 | Genomicfx, Inc. | Methode de quantification relative d'acides nucleiques lies |
Non-Patent Citations (2)
| Title |
|---|
| See also references of EP1573064A2 * |
| WATSON RACHEL E B ET AL: "A short-term screening protocol, using fibrillin-1 as a reporter molecule, for photoaging repair agents" JOURNAL OF INVESTIGATIVE DERMATOLOGY, Bd. 116, Nr. 5, Mai 2001 (2001-05), Seiten 672-678, XP002283191 ISSN: 0022-202X * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2866233A1 (fr) * | 2004-02-18 | 2005-08-19 | Vincience | Composition dermatologique et/ou cosmetique contenant des polypeptides |
| WO2005089706A1 (fr) * | 2004-02-18 | 2005-09-29 | Societe D'extraction Des Principes Actifs Sa (Vincience) | Composition dermatologique et/ou cosmetique contenant des polypeptides |
| US8012938B2 (en) | 2004-02-18 | 2011-09-06 | Isp Investments Inc. | Dermatological and/or cosmetic composition containing polypeptides |
| US9168215B2 (en) | 2009-07-16 | 2015-10-27 | L'oreal | Cosmetic use of lacritin-type polypeptides |
| WO2015031708A1 (fr) * | 2013-08-30 | 2015-03-05 | The Procter & Gamble Company | Procédés d'identification d'agents cosmétiques pour le traitement d'une dyschromie périorbitaire et systèmes associés |
| NO20170739A1 (en) * | 2017-05-04 | 2018-11-05 | Patogen As | Novel virus in Fish and Method for detection |
| NO344051B1 (en) * | 2017-05-04 | 2019-08-26 | Patogen As | Novel virus in Fish and Method for detection |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003293839A1 (en) | 2004-07-22 |
| WO2004059001A3 (fr) | 2005-03-03 |
| DE10260928A1 (de) | 2004-07-08 |
| EP1573064A2 (fr) | 2005-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE10100121A1 (de) | Verfahren zur Bestimmung des Hautstreß oder der Hautalterung in vitro | |
| DE10100127A1 (de) | Verfahren zur Bestimmung der Homeostase der Haut | |
| DE69535428T2 (de) | Verfahren zum Auffinden von differentiel exprimierte Gene | |
| DE10296990B4 (de) | Verwendung eines Biochips zur Diagnose von Sepsis und sepsisähnlichem Syndrom | |
| DE10155600B4 (de) | Nukleinsäure-Array | |
| DE10234524A1 (de) | Nukleinsäurearray | |
| DE10260931B4 (de) | Verfahren zur Bestimmung der Homeostase behaarter Haut | |
| EP1573064A2 (fr) | Procede de determination de marqueurs de la peau du visage humain | |
| Fletcher et al. | Gene expression analysis of EpiDerm™ following exposure to SLS using cDNA microarrays | |
| DE60009530T2 (de) | Genetische toxizitätsmarker, herstellung und verwendung | |
| EP1658380A2 (fr) | Procede pour determiner des marqueurs de cycle capillaire | |
| DE60117180T2 (de) | Verfahren zur messung des aktivierungszustands von signalwegen in zellen | |
| DE10100122A1 (de) | Verfahren zur Bestimmung der Hautalterung in vitro | |
| EP0698122B1 (fr) | Agent de diagnostic complexe de l'expression genetique et son procede d'application en diagnostic medical et pour isoler des genes | |
| Korostynski et al. | High-throughput gene expression profiling of opioid-induced alterations in discrete brain areas | |
| WO2004058991A1 (fr) | Procede de determination de l'etat enzymatique de la peau humaine in vitro | |
| WO2000071747A2 (fr) | Systeme de detection aux fins de separation des constituants d'un prelevement, sa production et son utilisation | |
| WO2014068092A2 (fr) | Procede de determination du vieillissement independamment du sexe | |
| DE10340395A1 (de) | Verfahren zur Erkennung akuter generalisierter entzündlicher Zustände (SIRS) | |
| WO2004005542A2 (fr) | Procede d'identification de genes de la peau regules specifiquement a une infection | |
| WO2009015799A2 (fr) | Détection de la résistance au platine | |
| Kim et al. | Ranking Candidate Genes for the Biomarker Development in a Cancer Diagnostics | |
| DE10136656A1 (de) | Biochip und Verfahren für die Ermittlung von Sondensequenzen für einen Biochip | |
| DE10207971A1 (de) | Verfahren zur Identifizierung Nebenwirkungs-relevanter Markerprofile | |
| DE20023863U1 (de) | Microarray erhältlich durch Gesamt-Chromosomanalyse von Protein-DNA-Wechselwirkung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU BR BY CA CN DZ EG ID IL IN JP KR MX NO NZ PL RU SG UA US UZ VN YU ZA |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2003789223 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 2003789223 Country of ref document: EP |
|
| NENP | Non-entry into the national phase |
Ref country code: JP |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |